Breaking Barriers: The Benefits Of Being A Swiss Biotech
Executive Summary
The lack of distractions from a large domestic market and a close proximity of research centers are just two advantages for the flourishing Swiss biotech sector, which enjoyed a bumper year in 2021, says its industry association.
You may also be interested in...
Lundbeck And Axsome Rival Candidate Data Raise Prospects For First Alzheimer’s Agitation Approvals
The firms unveiled positive Phase III data from their respective assets for treating the agitation seen in Alzheimer’s disease with Lundbeck’s candidate set to become first-to-market for the challenging behavioral symptom.
Executives On The Move: AbbVie, FSD Pharma and More
Recent executive changes in the industry include C-suite changes at AbbVie and Pharnext. Meanwhile, new directors were appointed at Zydus Lifesciences and FSD Pharma.
Acousia To Refresh Stagnant Hearing Loss Space With New Potassium Channel Approach
The German biotech plans to prevent chemotherapy-induced hearing loss and treat chronic hearing loss by targeting a potassium channel in the ear’s sensory hair cells as it tackles a widespread but side-lined area.